abs80.txt	programmed	cell	death	1	(pd-1)	and	its	ligand	(pd-l1)	are	key	physiologicsuppressors	of	the	cytotoxic	immune	reaction		however		to	date		the	combinationof	pd1/pd-l1	expression	and	tumor-infiltrating	lymphocytes	(tils)	andantigen-presenting	cells	has	been	only	minimally	reported	in	breast	carcinoma		inparticular	in	relation	to	her2-positive	cases		the	goal	of	this	study	was	toevaluate	both	cellular	tumoral	immune	reaction	and	pd-l1/pd1	distribution	inher2-positive	cases		as	well	as	any	associations	with	clinical	outcome	usingconventional	chemotherapy	combined	with	her2	blocking		multicolorimmunohistochemical	multiplex	assays	simultaneously	demonstrating	pd1		pd-l1		andcd8	or	pd-l1		cd3		and	cd163	were	performed	on	tissue	microarrays	(tma)representing	216	pretreatment	cases	of	her2-positive	invasive	breast	carcinoma	pd-l1	expression	was	identified	in	38	cases	(18%)		including	12	cases	(6%)	withpd-l1	labeling	of	tumor	cells	and	26	cases	(12%)	with	pd-l1	labeling	of	immunecells	only		ten	of	12	cases	with	pd-l1	staining	of	tumor	cells	showed	staining	ofassociated	immune	cells	as	well		with	this	assay	method		pd1	was	detectable	inmany	fewer	cases	(6	cases	or	3%)		pd-l1	expression	was	positively	associated	withhigh	nottingham	grade		negative	er	and	pr		the	absence	of	lymph	node	metastasis	and	high	levels	of	cd8+	cells		the	overall	survival	by	univariate	analysis	waspositively	associated	with	lower	tumor	stage		the	absence	of	lymph	nodemetastasis		pd-l1	expression		and	high	levels	of	cd8+	cells		therefore		our	datasuggest	cytotoxic	immune	reaction	mediated	by	cd8-positive	t	cells	and	pd-l1expression	may	predict	a	better	outcome	in	patients	with	her2-positive	breastcarcinoma	managed	with	conventional	chemotherapy	and	her2-blocking	therapy		thesefindings	recommend	clinical	trials	utilizing	checkpoint	blocking	immunotherapy	insome	form	for	her2-positive	breast	cancer	
